Butters Oliver, Young Kate, Cunningham David, Chau Ian, Starling Naureen
Gastrointestinal Unit, Royal Marsden Hospital, London, United Kingdom.
Front Oncol. 2019 Jul 16;9:618. doi: 10.3389/fonc.2019.00618. eCollection 2019.
In 2014, the survival benefits seen in REGARD and RAINBOW studies led the way for the regulatory approval of ramucirumab in the second line setting in oesophagogastric (OG) cancer. Trials of other drugs targeting the vascular endothelial growth factor (VEGF) pathway have met with mixed results but this remains an important pathway for evaluation in OG cancer. Perhaps the most interesting ongoing trials are those which target VEGF in combination with immunotherapy, which have a sound scientific rationale. Given the emerging role of immunotherapy in OG cancer, this is an important area of innovation. This review aims to outline targeting VEGF in OG cancer, the rationale behind the continued interest in this mechanism and possible future directions in combination with immunotherapy.
2014年，REGARD和RAINBOW研究中观察到的生存获益为雷莫西尤单抗在食管胃癌（OG癌）二线治疗中的监管批准铺平了道路。其他靶向血管内皮生长因子（VEGF）通路的药物试验结果不一，但这仍然是OG癌评估中的一个重要通路。也许目前最有趣的试验是那些将VEGF与免疫疗法联合应用的试验，其具有合理的科学依据。鉴于免疫疗法在OG癌中日益凸显的作用，这是一个重要的创新领域。本综述旨在概述OG癌中VEGF靶向治疗、对该机制持续关注背后的原理以及与免疫疗法联合应用的可能未来方向。
